Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid

Anticancer Drugs. 2015 Feb;26(2):232-5. doi: 10.1097/CAD.0000000000000169.

Abstract

Bone is a common site for tumor spread in patients with solid tumors. So far bisphosphonates have been the main pharmacological treatment option for patients with bone metastases. We present a case of bone metastatic gastric cancer treated with zoledronic acid at first and later with denosumab. After 1 year of denosumab treatment, the 18F-fluorodeoxyglucose (18F-FDG)-PET/computed tomography scan reassessment documented a metabolic complete response, even in the absence of specific antiblastic treatment. Whether denosumab can be used directly after pretreatment with bisphosphonates has yet to be addressed.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bone Density Conservation Agents / therapeutic use
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / secondary
  • Denosumab
  • Diphosphonates / therapeutic use*
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Imidazoles / therapeutic use*
  • Middle Aged
  • Positron-Emission Tomography / methods
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology
  • Treatment Outcome
  • Zoledronic Acid

Substances

  • Antibodies, Monoclonal, Humanized
  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • Fluorodeoxyglucose F18
  • Denosumab
  • Zoledronic Acid